LEVEL 4 A02BC01

Δραστικές

Φάρμακα

  • DRUGBANK - Esomeprazole
  • indication:

    For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.

  • pharmacology:

  • mechanism:

    Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H<sup>+</sup>/K<sup>+</sup>-ATPase in the gastric parietal cell. By acting specifically on the proton pump, Esomeprazole blocks the final step in acid production, thus reducing gastric acidity.

  • toxicity:

    Blurred vision, confusion, drowsiness, dry mouthflushingheadache, nausea, rapid heartbeat, sweating

  • absorprion:

    90%

  • halflife:

    1-1.5 hours

  • roouteelimination:

    Esomeprazole is extensively metabolized in the liver by the cytochrome P450 (CYP) enzyme system. Esomeprazole is excreted as metabolites primarily in urine but also in feces. Less than 1% of parent drug is excreted in the urine.

  • volumedistribution:

    * 16 L [healthy volunteers]

  • clearance: